<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="223061">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00178971</url>
  </required_header>
  <id_info>
    <org_study_id>020724</org_study_id>
    <nct_id>NCT00178971</nct_id>
  </id_info>
  <brief_title>Serotonin 1A Agonists and Cognition in Schizophrenia</brief_title>
  <official_title>Serotonin 1A Agonists and Cognition in Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Alliance for Research on Schizophrenia and Depression</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder
      who have been treated with antipsychotic medications. Patients will be assigned to take
      active medication (Buspar)or placebo along with their prescribed antispycotic medication for
      six weeks. Patients' memory and problem-solving ability will be tested before and after
      medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder
      who have been treated with olanzapine or risperidone for at least three months randomized to
      receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">October 2004</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This study will examine the effect on cognition of the addition of buspirone compared with addition of a sugar pill to patients treated with olanzapine or risperidone</measure>
    <time_frame>six weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>buspirone 15-30 mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adjunctive treatment with buspirone</intervention_name>
    <description>buspirone 15-30 mg qd</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet all of the following criteria to be eligible for participation in the
        current research study.

          1. Subjects will be males and females between 18-65 years of age;

          2. Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or
             Schizoaffective Disorder;

          3. The subjects or their legal guardian must sign the informed consent;

          4. Subjects currently being treated with olanzapine or risperidone for a duration of at
             least 3 months

        Exclusion Criteria:

          1. Subjects who are pregnant or lactating

          2. Subjects who have brain damage and/or neurological disorders

          3. Subjects who have current substance dependence

          4. Subjects unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Y Meltzer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatric Hospital at Vanderbilt</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <lastchanged_date>January 6, 2010</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Herbert Meltzer, M.D.</name_title>
    <organization>Vanderbilt University Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Serotonin</mesh_term>
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
